Genmab — Maj 2017
-
@stockbull. Mon ikke de fleste ser det sådan.
-
hvad får dig til at fremhæve Kymab? Deres aktiviteter ser imponerende ud - men er de i nærheden af klinikken, eller har de nogle særligt interessante programmer?
-
umiddelbart skyder de på ret meget - infektion, autoimmun, onkologi, hæmatologi. Men det ser ikke ud til at de har planer om IPO
-
de fik en 3. runde finansiering på usd 100m i november
-
The new studyes. http://ir.genmab.com/releasedetail.cfm?ReleaseID=1026834
-
Fra webcast: Darzalex act directly on Myeloma cells and as broad immunologic activity Peter Leibowitz has completed a Phase 2 study with progression free survival and M Protein depletion as endpoint. These data currently embargoed will be presentented at a major meeting later this year
-
Det var om smoldering myeloma. Måske denne ?
https://clinicaltrials.gov/ct2/show/NCT02316106 -
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind